[Screening and Verification of Antioxidant Small Molecular Compounds for Expansion of Human Hematopoietic Stem Cells Ex Vitro]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):585-593. doi: 10.19746/j.cnki.issn1009-2137.2019.02.045.
[Article in Chinese]

Abstract

Objective: To screen the antioxidant small molecular compounds with optimal efficiency of expansing the human hematopoietic stem cells (hHSC) In vitro based on antioxidant small molecular compound database of LKT laboratory, and to verify the effects of these compounds on the biological functions of hHSC.

Methods: The umbilial cord blood CD34+ cells were enriched by using the MACS beads; the absolute number and percentage of CD34+ cells and CD34+ CD49f+ cells were detected by high throughput flow cytometry after culture of hHSC with compounds in vitro for 1 week, the SR1 (1 μmol/L) was used as positive control, the candidate compounds were screened out; then 4 compounds were selected for follow-up experiments by comprehensive evaluation of concentration, safety and expansion efficacy, the optimal used concentrations of selected compounds were determined through the concentration gradient analysis, and CFC short-term colony-forming cell test was performed by using the determined concentration so as to verify the effect of compounds on the self-renewal, multilineage differentiation.

Results: Out of 85 antioxidant small molecular compounds, 4 compounds (C2968, D3331, B1753 and B3358) with obvious expansion efficacy for CD34+ cells and CD34+ CD49f+ cells were screened out by high throughput flow cytometry; their optimal concentrations of 4 compounds were 0.5 μmol/L for C2968, 1.5 μmol/L for D3331 and 1.5 μmol/L for B1753 and 15 μmol/L for B3358. The CFC assay showed the colony formation number in compound-treated group significantly increased as compared with control group, moreover the self-renewal and multilineage differentiation were maintained.

Conclusion: The antioxidant small molecular compounds C2968 (0.5 μmol/L), D3331 (1.5 μmol/L), B1753 (1.5 μmol/L) and B3358 (1.5 μmol/L) possess good expansion efficacy for hHSC, they can maintain hHSC self-renewal, at the same time ensure the multilineage differentiation potentiality of hHSC.

题目: 抗氧化小分子化合物体外扩增人造血干细胞的筛选和验证研究.

目的: 基于LKT实验室抗氧化小分子化合物库,筛选人造血干细胞(HSC)体外扩增效果最佳的小分子化合物,并初步验证其对人HSC生物学功能的影响。.

方法: 采用MACS磁珠富集脐带血CD34+细胞,体外加药培养1周后应用BD Fortessa高通量流式细胞术检测CD34+细胞及CD34+ CD49f+细胞的绝对数和比例,以SR1 (1 μmol/L)为阳性对照,筛选出多个候选化合物。对候选化合物浓度、安全系数、扩增效果等多方面因素进行综合考量后,选出C2968、D3331、B1753、B3358 4个化合物进行后续实验。通过浓度梯度分析初步确定4个化合物的最佳使用浓度,并在此浓度下进行CFC体外短期造血集落形成实验,以验证化合物对人HSC自我更新、多向分化两大生物学功能的影响。.

结果: 应用高通量流式细胞术检测85种抗氧化小分子化合物,筛选得到对人CD34+细胞及CD34+ CD49f+细胞具有显著扩增作用的4种化合物C2968、D3331、B1753、B3358。通过体外多浓度梯度稀释培养后,应用流式细胞术检测确定其最佳使用浓度,分别为C2968(0.5 μmol/L)、D3331(1.5 μmol/L)、 B1753(1.5 μmol/L)、B3358(15 μmol/L)。体外短期造血集落形成实验结果显示,化合物处理组较对照组集落形成数量明显增多,多能祖细胞多向分化潜能得以维持。.

结论: C2968、D3331、B1753、B3358 4种抗氧化小分子化合物在维持人HSC自我更新的同时能够保证其多向分化潜能,具有较好的体外扩增效果。.

MeSH terms

  • Antigens, CD34
  • Antioxidants
  • Cells, Cultured
  • Fetal Blood
  • Flow Cytometry
  • Hematopoietic Stem Cells*
  • Humans

Substances

  • Antigens, CD34
  • Antioxidants